AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06307509 — intervention group
Intervention type: OTHER
Intervention: Diagnosis of sepsis
Description: Patients will be recruited on the basis of a diagnosis of sepsis, as this is the exposure of interest
Study NCT05181397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants in tocilizumab group will receive intravenous 8mg/kg tocilizumab.
Study NCT05721573 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABC008
Description: Given by subcutaneous injection
Study NCT03722693 — intervention group
Intervention type: DEVICE
Intervention: Functional electrical stimulation based treatment
Description: Two types of multi-pad electrodes will be used during this study. Both were designed for covering the extrinsic muscles of the hand. Electrodes are comprised of 8 pads that act as anodes and 32 pads that acted as cathodes. The shape and distribution of the conductive pads within the electrodes were designed considering the motor points for achieving different movement primitives (wrist extension, wrist flexion, fingers extension, fingers flexion, index extension, index flexion, thumb extension, and thumb flexion). Each participant will receive 5 assessment sessions:1. before starting the interventions, 2. after the 7 days of standard care, 3. after 7 days of first FES based protocol, 4.after another 7 days of standard care and 5. after seven days of the other FES based intervention
Study NCT06315101 — intervention group
Intervention type: DRUG
Intervention: Chinese Herbal Medicine
Description: Patients were treated with Chinese herbal medicine (CHM). CHM refers to the administration of a syndrome-specific herbal formula prescribed by a Traditional Chinese Medicine (TCM) physician after an uHCC diagnosis. Physicians determine the formula based on tongue and pulse examinations and personalized TCM syndromes derived from individual patient symptoms, adhering to established therapeutic principles and long-term clinical experience of physicians. The CHM formula applied in the study followed overarching TCM strategies, including reinforcing spleen qi, harmonizing liver qi, addressing blood stasis, and detoxification.
Study NCT05744583 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Packed red cell transfusion
Description: Type O RhD negative packed red cell transfusion during prehospital emergency care
Study NCT05744583 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole blood transfusion
Description: Type O RhD positive, low titer whole blood transfusion during prehospital emergency care
Study NCT05848323 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 4-week Relaxation Training
Description: A 4-session telehealth Relaxation Training intervention for multiple sclerosis fatigue that is derived from evidence-based multicomponent CBT for multiple sclerosis fatigue. The intervention is based on the cognitive behavioral model of fatigue in multiple sclerosis. The intervention involves 4, 30-60-minute sessions including the following content a) education about fatigue in multiple sclerosis and the cognitive behavioral model of multiple sclerosis fatigue, b) treatment rationale, b) didactic and experiential training in relaxation techniques such as diaphragmatic breathing, progressive muscle relaxation, autogenic relaxation, and guided imagery, and c) goal setting and problem-solving barriers focused on integrating relaxation practices into daily routine.
Study NCT05848323 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 4-week Behavioral Activation
Description: A 4-session telehealth Behavioral Activation intervention for multiple sclerosis fatigue that is derived from evidence-based multicomponent CBT for multiple sclerosis fatigue. The intervention is based on the cognitive behavioral model of fatigue in multiple sclerosis. The intervention involves 4, 30-60-minute sessions including the following content a) education about fatigue in multiple sclerosis, the cognitive behavioral model of multiple sclerosis fatigue, and self-monitoring activity and energy, b) treatment rationale, c) identification of values/priorities to guide activities, d) activity planning, e) goal setting and problem-solving barriers to engaging in activities.
Study NCT05721573 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ABC008
Description: Given by subcutaneous injection
Study NCT06320522 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ketone Monoester
Description: Commercial dietary supplement intended raise blood ketone body levels
Study NCT06320522 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo drink (2mM sucrose octaacetate) taste and volume matched to the ketone monoester drinks
Study NCT05797883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX/FOLFIRI
Description: mFOLFOX6 ：oxaliplatin 85mg/m² IV infusion 2h d1, 5-FU 400mg/m² push d1, Then 5-FU 1200mg/(m2▪d)×2d+Levofolinic Acid 200mg/m² continuous mixed infusion for 46-48h (total 5-FU 2400mg/m²); FOLFIRI ：Irinotecan 180mg/m ² static pulse infusion 30min\~90min d1, 5-FU 400mg/m² push d1, Then 5-FU 1200mg/(m2▪d)×2d+ Levofolinic Acid 200mg/m² continuous mixed infusion for 46-48h (total 5-FU 2400mg/m²); The combination of cetuximab/bevacizumab and other targeted agents depends on the patient.
Study NCT05134714 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CAD/CAM zircon band and loop space maintainer
Description: Solid monolithic zirconia material which utilizes CAD/CAM technology for its designing and milling of the restoration will be used for fabrication of the space maintainer.
Study NCT05134714 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CAD/CAM zircon band and loop space maintainer
Description: Solid monolithic zirconia material which utilizes CAD/CAM technology for its designing and milling of the restoration will be used for fabrication of the space maintainer.
Study NCT05134714 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional metal band and loop space maintainer
Description: Stainless steel appropriate band will be selected according to the size of the abutment teeth and then design of the loop will be obtained, then will be send to the laboratory for soldering.
Study NCT05134714 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional metal band and loop space maintainer
Description: Stainless steel appropriate band will be selected according to the size of the abutment teeth and then design of the loop will be obtained, then will be send to the laboratory for soldering.
Study NCT06313996 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Specified dose on specified days
Study NCT06313996 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Specified dose on specified days
Study NCT06313996 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: Specified dose on specified days
Study NCT06313996 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Specified dose on specified days
Study NCT06313996 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Specified dose on specified days
Study NCT06313996 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bendamustine
Description: Specified dose on specified days
Study NCT06313996 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Specified dose on specified days
Study NCT06313996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Specified dose on specified days
Study NCT06313996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liso-cel
Description: Specified dose on specified days
Study NCT05564546 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FeNO (fractional exhaled nitric oxide)
Description: FeNO measurement is a marker of airway inflammation. It is a non-invasive examination for the patient, easy to perform for healthcare personnel, the measurement of NO in exhaled air is one of the only non-invasive and reproducible examinations allowing the detection of inflammation airways.~The FeNO will be measured by an electrochemical NO analyzer of the NiOx Vero type (Circassia, The Surgical Company) and expressed in particles per billion (ppb). The objective and reproducible measurement of NO production by the bronchial mucosa is a reflection of the degree of airway inflammation. The measurement of exhaled NO is part of diagnostic health technologies aimed at quantifying airway inflammation, especially in asthmatic patients.~FeNO is considered normal for values of 16-25 ppb. A FeNO value > 25 ppb will be a reason for consultation at the Martinique Hospital for additional assessment.
Study NCT05564546 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FeNO (fractional exhaled nitric oxide)
Description: FeNO measurement is a marker of airway inflammation. It is a non-invasive examination for the patient, easy to perform for healthcare personnel, the measurement of NO in exhaled air is one of the only non-invasive and reproducible examinations allowing the detection of inflammation airways.~The FeNO will be measured by an electrochemical NO analyzer of the NiOx Vero type (Circassia, The Surgical Company) and expressed in particles per billion (ppb). The objective and reproducible measurement of NO production by the bronchial mucosa is a reflection of the degree of airway inflammation. The measurement of exhaled NO is part of diagnostic health technologies aimed at quantifying airway inflammation, especially in asthmatic patients.~FeNO is considered normal for values of 16-25 ppb. A FeNO value > 25 ppb will be a reason for consultation at the Martinique Hospital for additional assessment.
Study NCT05564546 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spirometry
Description: Spirometry tests will assess lung function. It is a safe and painless test to measure lung volumes and expiratory flows.~Ventilatory function is assessed by simple spirometry parameters such as forced expiratory volume in the first second (FEV1, in litres), vital capacity (CV, in litres), and the FEV1/CV ratio.~The results of the spirometry will be compared with the theoretical or predicted values calculated according to age, sex, height.The FEV1/CV ratio as a percentage is an indicator of the level of bronchial obstruction.~Spirometry is considered normal for CV values ≥80% and FEV1/FVC ≥0.70 of the predicted value. A value of CV \<80% or FEV \<80% of the predicted value will be a reason for consultation at the Martinique hospital for additional assessment.
Study NCT05564546 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spirometry
Description: Spirometry tests will assess lung function. It is a safe and painless test to measure lung volumes and expiratory flows.~Ventilatory function is assessed by simple spirometry parameters such as forced expiratory volume in the first second (FEV1, in litres), vital capacity (CV, in litres), and the FEV1/CV ratio.~The results of the spirometry will be compared with the theoretical or predicted values calculated according to age, sex, height.The FEV1/CV ratio as a percentage is an indicator of the level of bronchial obstruction.~Spirometry is considered normal for CV values ≥80% and FEV1/FVC ≥0.70 of the predicted value. A value of CV \<80% or FEV \<80% of the predicted value will be a reason for consultation at the Martinique hospital for additional assessment.
Study NCT05564546 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical examination
Description: A pulmonary clinical examination will be carried out by the investigator, including:~* Cough,~* Sputum,~* Vesicular murmur (MV),~* Added noises (BSA),~* Vocal vibrations (VV),~* Tympanism,~* Dullness,~* Signs of acute respiratory distress (ARD),~* ...
Study NCT05564546 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical examination
Description: A pulmonary clinical examination will be carried out by the investigator, including:~* Cough,~* Sputum,~* Vesicular murmur (MV),~* Added noises (BSA),~* Vocal vibrations (VV),~* Tympanism,~* Dullness,~* Signs of acute respiratory distress (ARD),~* ...
Study NCT05564546 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interrogation
Description: Participants will undergo an interview with the medical team to collect the following information in particular:~Age, size, sex, medical history, smoking status, current treatments, potential symptoms, date of first symptoms, clinical manifestations experienced (respiratory, digestive, neurological, cardiac, psychiatric, visual, skin disorders, etc.) place of residence, concentration H2S in ppm on the site, presence of sand mist in the environment, etc.
Study NCT05564546 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interrogation
Description: Participants will undergo an interview with the medical team to collect the following information in particular:~Age, size, sex, medical history, smoking status, current treatments, potential symptoms, date of first symptoms, clinical manifestations experienced (respiratory, digestive, neurological, cardiac, psychiatric, visual, skin disorders, etc.) place of residence, concentration H2S in ppm on the site, presence of sand mist in the environment, etc.
Study NCT05266898 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human papillomavirus 9-valent vaccine, recombinant
Description: Subunit vaccine against 9 genotypes of human papillomavirus (6, 11, 16, 18, 31, 33, 45, 52, 58)
Study NCT05330052 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Agilik
Description: The Agilik is a leg orthosis device supporting the knee joint, and is intended to be worn on one or both the legs. The device is customized for single patient use. It is composed of custom-fabricated polypropylene leg shells (thigh, calf and foot components) with joint supports, actuator, sensors, cabling and a battery waist pack. The Agilik is attached to the patient using straps - two on the thigh and two on the shank. A rotational linkage connects the thigh and calf portions of the device, is placed lateral to the knee joint, and is aligned with the knee center of rotation.
Study NCT05441098 — intervention group
Intervention type: OTHER
Intervention: Neoadjuvant therapy
Description: Preoperative systemic therapy for breast cancer patients
Study NCT05848323 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 4-week Cognitive Therapy
Description: A 4-session telehealth Cognitive Therapy intervention for multiple sclerosis fatigue that is derived from evidence-based multicomponent CBT for multiple sclerosis fatigue. The intervention is based on the cognitive behavioral model of fatigue in multiple sclerosis. The intervention involves 4, 30-60-minute sessions including the following content a) education about fatigue in multiple sclerosis, the cognitive behavioral model of multiple sclerosis fatigue, self-monitoring thoughts, and core beliefs, b) treatment rationale, b) labeling thoughts as helpful, unhelpful, or neutral, c) using distraction to cope with unhelpful thoughts, d) challenging and changing unhelpful thoughts, e) problem solving barriers to coping with or changing unhelpful thoughts.
Study NCT06446284 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EWM Training
Description: Training tasks will target Executive Working Memory areas of the brain. Task difficulty will be adaptively increased across the 5 weeks of training based on session-to-session performance.
Study NCT06446284 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Training
Description: Computerized tasks with comparable engagement that do not tap executive working memory processes
Study NCT05703464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elobixibat 10mg
Description: Patients of chronic constipation with loss of defecation desire are administered Elobixibat 10mg for 4 weeks
Study NCT06038929 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vagal nerve stimulant
Description: Vagus nerve stimulation involves using a device to stimulate the vagus nerve with electrical impulses. The implanted electrodes transmit electrical impulses travel to areas of the brain to treat conditions (intractable epilepsy, depression) and also send electrical impulses to the stomach.
Study NCT06731517 — intervention group
Intervention type: PROCEDURE
Intervention: intubation
Description: Double-Lumen Tube Intubation
Study NCT06730048 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Group
Description: An appointment will be made to meet with the students in the experimental group in a suitable classroom of the school. After the pre-test data, the students in the experimental group will be shown the preeclampsia case with virtual glasses for about 5-10 minutes. Then the post-test will be applied. A scenario including preeclampsia case and nursing care practices will be created in the virtual reality environment, and 10 experts will be consulted about the scenario before the students are shown it. This application will not have any side effects.
Study NCT06730048 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control group (placebo)
Description: After the pre-test data, the preeclampsia case will be explained to the students in the control group with the classical lecture method in the Women's Health and Diseases Nursing course and the post-test will be applied.
Study NCT05020366 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promoting Health through Parent Empowerment and the Activation of Routines
Description: Parents will receive a report of their child's current performance and adherence to World Health Organization recommendations in each intervention area. Parents will be coached to build consistent family mealtime routines, in which children are involved in meal preparation, food exploration, and play. They will receive education on appropriate serving sizes for young children and basic information nutrition recommendations. Predictable bedtime routines will be designed to incorporate calming sensory input to improve the transition to bed. Parents will be educated on screen time recommendations and help families brainstorm alternatives to screens, including family-based routines of movement and activity. Finally, parents will be coached to incorporate play into all newly adopted routines, as young children learn though play.
Study NCT05020366 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: For the control group, usual care will be enhanced by providing parents with a report of their child's performance and adherence to World Health Organization recommendations in the areas of healthy eating, physical activity, sedentary behavior and sleep. This report will consolidate data based on parent report, written logs, and actigraphy at baseline.
Study NCT04311281 — intervention group
Intervention type: BIOLOGICAL
Intervention: [F-18]FDDNP-PET
Description: \[F-18\]FDDNP, or 2-(1-{6-\[(2-\[F-18\]fluoroethyl)(methyl)amino\]-2- naphthyl}ethylidene)malononitrile, is a positron emission tomography (PET) radiotracer developed for the in vivo visualization of tau and amyloid-beta (Aβ) deposition in the brain.
Study NCT06731751 — intervention group
Intervention type: OTHER
Intervention: Management of spontaneous intracranial haemorrhage
Description: Admission to hospital for spontaneous intracranial haemorrhage management. This includes admission for observation, conservative or interventional (surgical or endovascular) management to both ward-based and critical care settings.
Study NCT05423366 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal Shock Wave Therapy (ESWT)
Description: The ESWT device is product of Elettronica Pagani, Italy.
Study NCT05423366 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Extracorporeal Shock Wave Therapy (ESWT)
Description: The ESWT device is product of Elettronica Pagani, Italy.
Study NCT04712513 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Dynamic cardiac CT perfusion imaging
Description: Multiple images of the heart are acquired with a clinical CT scanner after an intravenous bolus injection of contrast solution. The images are then analyzed to provide fractional flow reserve and myocardial perfusion values.
Study NCT06291623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycyrrhizin
Description: used as intracanal medication for one week
Study NCT06428032 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hand-Arm Bimanual Intensive Therapy Including Lower Extremities
Description: Structured bimanual tasks training, with gradual increase in motor difficulty, requiring increased postural adjustments and the use of the lower extremities.
Study NCT05691972 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane Contour
Description: a sterile, biodegradable, transparent gel of nonanimal cross-linked HA (20 mg/mL) with the addition of lidocaine hydrochloride (3 mg/mL)
Study NCT02800824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Study NCT02800824 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Uceris
Study NCT05851664 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: intubation by direct laryngoscopy
Description: intubation using a direct laryngoscopy type macintosh
Study NCT05851664 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intubation by videolaryngoscopy
Description: Intubation using a videolaryngoscope type McGrath
Study NCT05892549 — intervention group
Intervention type: DEVICE
Intervention: COVOICE application use - initial
Description: Recording (only once) of sound related to respiratory movements, coughing and voice using a mobile phone application
Study NCT05892549 — intervention group
Intervention type: DEVICE
Intervention: COVOICE application use - follow-up
Description: Daily recording of sound related to respiratory movements, coughing and voice using a mobile phone application. Duration: up to 30 days
Study NCT05838911 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study Group chest physiotherapy program combined with neuromuscular electrical stimulation (NMES)
Description: The patients in this group were received the same chest physiotherapy program combined with neuromuscular electrical stimulation of gluteus max., quadriceps, and calf muscles performed for 30 min /day for five days a week for three consecutive weeks.